References
- Leung A, Hon K, Leong K, et al. Measles: a disease often forgotten but not gone. Hong Kong Med J. 2018;24(5):512–520. doi:10.12809/hkmj187470.
- Gutierrez J, Rs I, Bs K. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901–907. doi:10.1111/j.1469-8749.2010.03717.x.
- Goodson J, Teleb N, Ashmony H, et al. Progress toward measles elimination – Eastern Mediterranean Region, 2013–2019. MMWR. 2020;69(15):439–445. doi:10.15585/mmwr.mm6915a2.
- Patterson M. Neurological complications of measles (Rubeola). Curr Neurol Neurosci Rep. 2020;20(2):2. doi:10.1007/s11910-020-1023-y.
- Garg R, Mahadevan A, Malhotra H, et al. Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29(5):e2058. doi:10.1002/rmv.2058.
- Wendorf K, Winter K, Zipprich J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017;65(2):226–232. doi:10.1093/cid/cix302.
- Ferren M, Horvat B, Mathieu C. Measles encephalitis: towards new therapeutics. Viruses. 2019;11(11):1017. doi:10.3390/v11111017.
- Hashimoto K, Hosoya M. Advances in antiviral therapy for subacute sclerosing panencephalitis. Mol Basel Switz. 2021;26(2):427. doi:10.3390/molecules26020427.
- Sliva J, Pantzartzi CN, Votava M. Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36(8):1878–1905. doi:10.1007/s12325-019-00995-6.
- Papetti L, Amodeo ME, Sabatini L, et al. Subacute sclerosing panencephalitis in children: the archetype of non-vaccination. Viruses. 2022;14(4):733. doi:10.3390/v14040733.